Sign inJoin waitlistJoin the waitlist

Lisa E. Flaum

Associate Professor, Feinberg School of Medicine · Feinberg School of Medicine

Credentials: · · ·

History

Feinberg School of Medicine
Present

McGaw Medical Center of Northwestern University
Until 2005
McGaw Medical Center of Northwestern University
Until 2001
Georgetown University School of Medicine
1998

Research

Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations
Journal of the American College of Cardiology · 1995 · 488 citations
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant…
Journal of Clinical Oncology · 2021 · 122 citations
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer
Molecular Cancer Therapeutics · 2017 · 109 citations

William Gradishar
16 papers
Massimo Cristofanilli
9 papers
Ami Shah
8 papers
AB
Amir Behdad
6 papers
Leonidas Platanias
6 papers
CS
Cesar Santa-Maria
5 papers
SJ
Sarika Jain
5 papers
Amye Tevaarwerk
4 papers
Angela DeMichele
4 papers
AW
Antonio Wolff
4 papers
Ben Park
4 papers
Brian Burnette
4 papers

Clinical trials

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2029
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Site PI · Recruiting · Phase 2
Massachusetts General Hospital
2021–2028